Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC) : Results from EXIST-1 and EXIST-2.

10619 Background: The efficacy and safety of everolimus, an oral mTOR inhibitor, was assessed in two randomized, double-blind, placebo-controlled, phase 3 trials: EXIST-1 (NCT00789828) and EXIST-2 ...